CRSP

CRISPR Therapeutics AG: 2025 Annual Report (10-K) Summary

Business Context and Reporting Period

This summary covers the fiscal year ended December 31, 2025. CRISPR Therapeutics AG is a biopharmaceutical company developing CRISPR-based therapeutics. The company operates four core franchises: hemoglobinopathies (led by the approved therapy CASGEVY), in vivo gene editing, CAR T cell therapies, and regenerative medicine. The company is incorporated in Switzerland and trades on the Nasdaq Global Market under the symbol CRSP.

Key Financial Metrics (Year Ended Dec 31, 2025)

Note: The filing text does not provide specific gross margin or operating margin percentages due to the company's pre-commercial revenue status and significant R&D expenditures.

Material Changes vs. Prior Period

• Revenue Decline: Total revenue dropped to $3.5 million from $37.3 million in 2024. This was driven by the absence of collaboration revenue from Vertex Pharmaceuticals in 2025, compared to $35.0 million recognized in 2024 from research milestones.
• Increased Collaboration Expense: Collaboration expense, net, rose significantly to $213.5 million from $120.7 million. This increase is primarily due to the expiration of the cost deferral option for the CASGEVY program in 2025. Previously, the company could defer costs exceeding $110.3 million annually; this deferral is no longer available, leading to higher recognized expenses.
• Acquired In-Process R&D: The company recorded $96.3 million in acquired in-process research and development expenses in 2025, related to the new collaboration with Sirius Therapeutics. There was no such expense in 2024.
• Net Loss Expansion: Net loss increased by approximately $215 million year-over-year, reflecting the combination of lower revenue and higher operating expenses.

Guidance, Outlook, and Management Commentary

• Liquidity Outlook: Management expects cash, cash equivalents, and marketable securities of approximately $1.98 billion to be sufficient to fund operations for at least the next 24 months.
• Profitability: The company anticipates incurring continued losses for the foreseeable future. Expenses are expected to increase as the company advances clinical trials and commercializes CASGEVY.
• Clinical Progress:
  • CASGEVY: Positive data presented at the American Society of Hematology (ASH) meeting in December 2025 showed 100% of pediatric patients with Sickle Cell Disease (SCD) and 100% of those with Transfusion-Dependent Beta Thalassemia (TDT) achieved primary endpoints (freedom from vaso-occlusive crises or transfusion independence).
  • CTX310 (In Vivo): Phase 1 data presented in November 2025 demonstrated durable reductions in ANGPTL3, triglycerides, and LDL-C. The program has advanced to Phase 1b.
  • Zugo-cel (CAR T): Encouraging data in autoimmune diseases (SLE) and oncology (LBCL) support advancement into Phase 2 trials.
• Strategic Partnerships: In May 2025, the company entered a collaboration with Sirius Therapeutics for siRNA-based programs (CTX611), involving an upfront payment and share issuance.

Risks and Contingencies

• Intellectual Property Litigation: In Q4 2025, ToolGen, Inc. initiated a lawsuit alleging patent infringement by CASGEVY. The outcome is uncertain and could materially harm the business.
• Regulatory and Safety Risks: Gene editing therapies face rigorous regulatory scrutiny. Adverse events or delays in clinical trials could prevent approval or commercialization.
• Capital Requirements: The company will need to raise substantial additional funding in the future, which may dilute shareholders. Failure to raise capital could force delays in development programs.
• Collaboration Dependency: Vertex Pharmaceuticals controls the development and commercialization of CASGEVY. Disagreements or delays by Vertex could impact CRISPR's revenue and cost-sharing obligations.

Key Facts for Investor Verification

• Cash Runway: Verify the sufficiency of the $1.98 billion cash position against the projected burn rate, given the loss of the CASGEVY cost deferral mechanism.
• ToolGen Litigation: Monitor the status of the patent infringement lawsuit filed by ToolGen regarding CASGEVY.
• CASGEVY Commercialization: Track Vertex's commercialization efforts and the resulting revenue share (40% to CRISPR) versus the now fully recognized cost share.
• Sirius Collaboration: Assess the progress of the CTX611 program and the financial impact of the $96.3 million upfront IPR&D expense.
• Regulatory Milestones: Watch for FDA/EMA decisions on pediatric indications for CASGEVY and the progression of CTX310 and zugo-cel into Phase 2.